Artia Global Partners LP Purchases New Holdings in Oruka Therapeutics, Inc. $ORKA

Key Points

• Artia Global Partners purchased 33,400 shares of Oruka Therapeutics valued at approximately $3.18 million, while institutional investors collectively own 56.44% of the company.
• Oruka shares opened at $99.44 after declining 2.3%; the company reported a quarterly loss of $0.55 per share, missing analyst expectations by $0.04.
• Analysts remain broadly bullish, with 10 Buy ratings and one Sell rating producing a “Moderate Buy” consensus and an average price target of $134.30, although insiders sold 83,116 shares worth $6.64 million over the past three months.

Artia Global Partners LP purchased a new position in shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 33,400 shares of the company's stock, valued at approximately $3,179,000. Artia Global Partners LP owned 0.05% of Oruka Therapeutics at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of ORKA. Legal & General Group Plc purchased a new position in Oruka Therapeutics in the second quarter valued at about $28,000. BNP Paribas Financial Markets raised its holdings in shares of Oruka Therapeutics by 464.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company's stock worth $31,000 after purchasing an additional 2,306 shares during the period. Royal Bank of Canada lifted its stake in Oruka Therapeutics by 47.2% in the fourth quarter. Royal Bank of Canada now owns 1,139 shares of the company's stock valued at $34,000 after purchasing an additional 365 shares during the last quarter. Los Angeles Capital Management LLC purchased a new position in Oruka Therapeutics in the fourth quarter valued at approximately $37,000. Finally, PNC Financial Services Group Inc. bought a new position in Oruka Therapeutics during the third quarter valued at $39,000. Institutional investors own 56.44% of the company's stock.

Oruka Therapeutics Trading Down 2.3%

Oruka Therapeutics stock opened at $99.44 on Thursday. Oruka Therapeutics, Inc. has a 1-year low of $14.61 and a 1-year high of $115.51. The firm has a market capitalization of $6.58 billion, a PE ratio of -48.99 and a beta of -0.34. The firm's 50 day simple moving average is $93.74 and its 200 day simple moving average is $66.89.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last released its quarterly earnings results on Monday, August 10th. The company reported ($0.55) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.04). Research analysts forecast that Oruka Therapeutics, Inc. will post -2.27 earnings per share for the current year.

Analysts Set New Price Targets

ORKA has been the topic of a number of recent research reports. BTIG Research reaffirmed a "buy" rating and set a $151.00 price target on shares of Oruka Therapeutics in a research report on Tuesday, August 11th. Guggenheim restated a "buy" rating and issued a $200.00 price objective on shares of Oruka Therapeutics in a research note on Tuesday, August 11th. UBS Group increased their target price on shares of Oruka Therapeutics from $100.00 to $130.00 and gave the stock a "buy" rating in a research report on Wednesday, July 1st. Piper Sandler reiterated an "overweight" rating and set a $180.00 target price on shares of Oruka Therapeutics in a research report on Tuesday, June 2nd. Finally, HC Wainwright reissued a "buy" rating and issued a $120.00 price target on shares of Oruka Therapeutics in a research report on Monday, August 3rd. Ten investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Oruka Therapeutics has an average rating of "Moderate Buy" and a consensus target price of $134.30.

Insiders Place Their Bets

In related news, Director Carl Dambkowski sold 12,583 shares of the business's stock in a transaction dated Friday, June 12th. The stock was sold at an average price of $70.11, for a total transaction of $882,194.13. Following the completion of the transaction, the director directly owned 38,743 shares in the company, valued at $2,716,271.73. The trade was a 24.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Joana Goncalves sold 7,000 shares of the business's stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $111.84, for a total value of $782,880.00. Following the transaction, the insider owned 32,718 shares of the company's stock, valued at approximately $3,659,181.12. The trade was a 17.62% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 83,116 shares of company stock worth $6,636,533 over the last three months. Corporate insiders own 23.49% of the company's stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company's proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company's lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.

Want to see what other hedge funds are holding ORKA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source